PTC Therapeutics Company Profile (NASDAQ:PTCT)

About PTC Therapeutics

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTCT
  • CUSIP:
Key Metrics:
  • Previous Close: $11.56
  • 50 Day Moving Average: $8.95
  • 200 Day Moving Average: $7.52
  • 52-Week Range: $5.27 - $35.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.85
  • P/E Growth: 0.25
  • Market Cap: $469.32M
  • Outstanding Shares: 34,083,000
  • Beta: 0.61
  • Net Margins: -305.62%
  • Return on Equity: -80.50%
  • Return on Assets: -49.09%
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 6.93%
  • Quick Ratio: 6.93%
Additional Links:
Companies Related to PTC Therapeutics:

Analyst Ratings

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (?)
Ratings Breakdown: 9 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.18)
Consensus Price Target: $38.00 (171.23% upside)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
DateFirmActionRatingPrice TargetDetails
9/22/2016Jefferies GroupReiterated RatingHold$7.00View Rating Details
8/8/2016Citigroup Inc.Boost Price TargetNeutral$8.00 -> $9.00View Rating Details
8/7/2016Cowen and CompanyReiterated RatingHoldView Rating Details
8/5/2016JPMorgan Chase & Co.Lower Price TargetNeutral$18.00 -> $17.00View Rating Details
8/5/2016Credit Suisse Group AGSet Price TargetHold$6.00View Rating Details
8/5/2016WedbushReiterated RatingNeutral$10.00View Rating Details
4/18/2016Royal Bank Of CanadaReiterated RatingSector Perform$9.00View Rating Details
4/17/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$39.00View Rating Details
3/1/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $100.00View Rating Details
2/29/2016Bank of America Corp.DowngradeBuy -> NeutralView Rating Details
10/16/2015Roth CapitalReiterated RatingHold$63.00View Rating Details
6/17/2015Deutsche Bank AGReiterated RatingBuy$115.00View Rating Details
(Data available from 9/30/2014 forward)


Earnings History for PTC Therapeutics (NASDAQ:PTCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)ViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
Current Year EPS Consensus Estimate: $-4.95 EPS
Next Year EPS Consensus Estimate: $-3.64 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.52)($1.00)($1.28)
Q2 20163($1.48)($0.90)($1.28)
Q3 20163($1.37)($0.90)($1.16)
Q4 20163($1.16)($0.50)($0.93)
Q1 20171($0.79)($0.79)($0.79)
Q2 20171($1.05)($1.05)($1.05)
Q3 20171($0.72)($0.72)($0.72)
Q4 20171($1.05)($1.05)($1.05)
(Data provided by Zacks Investment Research)


Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for PTC Therapeutics (NASDAQ:PTCT)
Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 83.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
DateHeadline logoPtc Therapeutics Inc. (PTCT): Camber Capital Management Adds 500000 Shares to Its Position - Insider Monkey (blog) (NASDAQ:PTCT) - September 30 at 3:25 PM logoETF’s with exposure to PTC Therapeutics, Inc. : September 30, 2016 (NASDAQ:PTCT) - September 30 at 3:25 PM
News IconNews review of 2 biotech stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - The Voice Registrar (NASDAQ:PTCT) - September 28 at 12:05 PM
News IconSteering Attention Towards Earnings; Analysts Weigh in on PTC ... - Frisco Fastball (NASDAQ:PTCT) - September 25 at 6:08 PM
News IconPTC Therapeutics, Inc. (NASDAQ:PTCT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Scibility Media (NASDAQ:PTCT) - September 23 at 6:23 PM
News IconStocks Trending Alert: DDR Corp (NYSE:DDR), PTC Therapeutics, Inc. (NASDAQ:PTCT) - NYSE Journal (press release) (NASDAQ:PTCT) - September 22 at 6:33 PM
News Icon2 Biotech Stocks News And Price Trends: PTC Therapeutics ... - The Voice Registrar (NASDAQ:PTCT) - September 22 at 6:33 PM logoJefferies Examines The Effect Of Sarepta's Drug Approval On PTC Therapeutics (NASDAQ:PTCT) - September 21 at 10:57 AM logoPTC Therapeutics (PTCT) calls active on FDA approval of Sarepta's (SRPT) eteplirsen - (NASDAQ:PTCT) - September 20 at 12:09 PM logoPTC Therapeutics Gets Big Boost From Sarepta's DMD Drug Approval - Benzinga (NASDAQ:PTCT) - September 20 at 12:09 PM logoPTC Therapeutics Gets Big Boost From Sarepta's DMD Drug Approval (NASDAQ:PTCT) - September 19 at 6:50 PM logoPTC Therapeutics Inc. (PTCT) Has Jumped To Nearly A 7-Month High (NASDAQ:PTCT) - September 19 at 11:28 AM logoSarepta's Drug Is Stuck in the FDA Quagmire (SRPT) (NASDAQ:PTCT) - September 16 at 6:40 PM
News IconBiotech Stocks Worth Chasing: Rexahn Pharmaceuticals, Inc. (RNN ... - The Independent Republic (NASDAQ:PTCT) - September 16 at 10:27 AM
News IconChart of The Day: Is Major Move Coming For PTC Therapeutics, Inc. After This Bearish Multiple Bottom? - Chester News (NASDAQ:PTCT) - September 16 at 10:27 AM logoNoteworthy Wednesday Option Activity: STAR, GE, PTCT (NASDAQ:PTCT) - September 15 at 10:27 AM
News IconShares Climbing Higher Session: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Post News (NASDAQ:PTCT) - September 14 at 7:01 PM
News IconStock Perspective: PTC Therapeutics, Inc. (NASDAQ:PTCT) Company Earnings Watch - Frisco Fastball (NASDAQ:PTCT) - September 14 at 7:01 PM logoPTC Therapeutics Reports Inducement Grants Under Nasdaq ... - PR Newswire (press release) (NASDAQ:PTCT) - September 14 at 7:01 PM
News IconMy Watchlist for Tuesday, September 13 (NASDAQ:PTCT) - September 12 at 6:33 PM logoETF’s with exposure to PTC Therapeutics, Inc. : September 9, 2016 (NASDAQ:PTCT) - September 9 at 11:40 AM logoShares Trading unchanged at $8.01 (PTCT) PTC Therapeutics Recognizes World... - Finance Daily (NASDAQ:PTCT) - September 7 at 7:02 PM logoPTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website (NASDAQ:PTCT) - September 7 at 10:30 AM
News IconStock Gapping Lower Before the Bell: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Post News (NASDAQ:PTCT) - August 29 at 6:41 PM
News IconPTC Therapeutics, Inc. (NASDAQ:PTCT) Near to Lift Curtain on September 2016 Earnings - The Voice Registrar (NASDAQ:PTCT) - August 29 at 6:41 PM logoETF’s with exposure to PTC Therapeutics, Inc. : August 25, 2016 (NASDAQ:PTCT) - August 25 at 12:03 PM logo22nd Century : Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century (NASDAQ:PTCT) - August 22 at 11:33 AM logoResearch Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century (NASDAQ:PTCT) - August 22 at 11:33 AM logoPTC THERAPEUTICS, INC. Financials (NASDAQ:PTCT) - August 13 at 6:38 PM logoETF’s with exposure to PTC Therapeutics, Inc. : August 12, 2016 (NASDAQ:PTCT) - August 12 at 7:04 PM logoPTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:PTCT) - August 11 at 7:30 PM logoA Look At Analyst Ratings Summary: PTC Therapeutics, Inc. (NASDAQ:PTCT), Tonix Pharmaceuticals Holding Corp ... - Review Fortune (NASDAQ:PTCT) - August 9 at 7:14 PM
News IconIntraday Movers: PDL BioPharma Inc (NASDAQ:PDLI), PTC Therapeutics, Inc. (NASDAQ:PTCT) - NYSE Journal (press release) (NASDAQ:PTCT) - August 8 at 11:41 AM logoPTC Therapeutics reports 2Q loss - Yahoo Finance (NASDAQ:PTCT) - August 6 at 9:44 AM logoPTC Therapeutics Inc. (PTCT) Jumps 6.83% on August 03 - (NASDAQ:PTCT) - August 5 at 7:12 PM logoEdited Transcript of PTCT earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:PTCT) - August 5 at 10:00 AM logoPTC Therapeutics Inc.: PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:PTCT) - August 4 at 7:28 PM logoPTC Therapeutics reports 2Q loss (NASDAQ:PTCT) - August 4 at 7:28 PM logoQ2 2016 PTC Therapeutics Inc Earnings Release - After Market Close (NASDAQ:PTCT) - August 4 at 10:07 AM logoRussell 2000 Headed 11% Higher, If Analysts Got The Components Right (NASDAQ:PTCT) - August 3 at 10:13 AM
News IconStock Attracting Analyst Attention: PTC Therapeutics, Inc. (NASDAQ:PTCT) - The Voice Registrar (NASDAQ:PTCT) - August 2 at 7:17 PM logoBenzinga's Top Initiations - Etsy Inc. (NASDAQ:ETSY), PTC ... - Benzinga (NASDAQ:PTCT) - August 1 at 6:44 PM logoA Look At Analyst Ratings Summary: PTC Therapeutics, Inc. (NASDAQ:PTCT), Xtera Communications Inc (NASDAQ ... - Review Fortune (NASDAQ:PTCT) - August 1 at 11:40 AM logoPTC Therapeutics Inc. (PTCT) Drops 13.02% on July 26 - (NASDAQ:PTCT) - July 28 at 10:14 AM
News IconRecommendation Trends for Investors: PTC Therapeutics, Inc. (NASDAQ:PTCT) - News Oracle (NASDAQ:PTCT) - July 26 at 7:21 PM logoPTC Therapeutics Inc. (PTCT) Drops 5.85% on July 25 - (NASDAQ:PTCT) - July 26 at 7:21 PM logoPTC Therapeutics downgraded by Credit Suisse (NASDAQ:PTCT) - July 26 at 7:33 AM logoPTC Therapeutics (PTCT) Offers Regulatory Update on Translarna; EMA Says Renewal Assessment Procedure Cannot be Completed by Mid-Year (NASDAQ:PTCT) - July 25 at 7:06 PM logoPTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe (NASDAQ:PTCT) - July 25 at 11:34 AM logoPTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) (NASDAQ:PTCT) - July 25 at 11:08 AM


PTC Therapeutics (NASDAQ:PTCT) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff